Kill Ideas Fast, Lead With Trust: Morgan Evans on Building a Medtech Ecosystem
Most founders get one piece of advice early and often: pick one thing and focus. Morgan Evans heard it too, and decided to build an ecosystem anyway. Morgan started out pre-med at Stanford and then moved into medtech, where she could have the impact she wanted with a little distance from the front line. She worked at a neuromodulation startup, co-founded her first company while getting her MBA at Northwestern, and spent two years in M&A at Medtronic before going back to startups in 2018.
Today her main focus is Agitated Solutions, which she co-founded with Northwestern cardiologist Dr. Micah Eimer to better detect and characterize PFO, a structural heart abnormality linked to stroke in young patients. Around it she has built an incubator (Moonshot Medical), two spinout device companies, an acquired business (SurgiSmoke), an early-stage fund (Engage Venture Partners), and a development consultancy (Avio Medtech Consulting). In her words, “the rest are hobbies,” and they happen to make money.
“The Best Thing You Can Do for an Idea Is Figure Out Why It Should Die”
Agitated Solutions started with a bad day in the echo lab. To make the contrast for a bubble study, clinicians mix air and saline by hand through a three-way stopcock, and nobody is formally trained to do it. An untrained staff member did it wrong, and the patient had a TIA. Dr. Eimer’s reaction was “There’s gotta be a better way.” That one problem led to so many ideas that the team spun 16 of them into a separate incubator.
Morgan’s filter is strict. First, the clinical problem has to be solved well for the masses. Early in her career she saw a surgeon’s five-minute technique take two hours in the first trial patient. Then she looks at the economics. Existing reimbursement is the easy sell, “but also, FYI, that’s what everyone’s chasing.” Without green-dollar savings, “you really, really, really, really have to have a strong black dollar argument.” She also checks market size: “If it’s gonna cost you a hundred million dollars to get there and it’s a hundred million dollar market, that math won’t math.” A mentor gave her a gentler way to think about it: put an idea on simmer instead of killing it.
“I Am a Better Investor Because I’m an Operator”
Morgan got into investing out of frustration. When she first raised money at 29, “no one looked like me,” in gender or in age. Rather than just complain, she co-founded Engage with Steve Sigmon to make medtech investing more accessible. Her roles feed each other. Through Avio she sees about 100 startups at a time, which shows her where companies struggle and helps her own teams avoid landmines others already hit. She keeps “church and state,” though: being an Avio client doesn’t earn a company an Engage check.
Trust, Intent, and Process
Duane and Morgan agreed that leading with trust is a risk worth taking. “With trust comes delegation,” Morgan said, and delegation is the only reason she can move fast. She separates trust from performance by looking at intent, and asks whether a mistake was a performance failure or a process failure. When an engineer sent the wrong drawing during a crunch-time V&V push, a mistake that cost $10K to $20K in expedite fees, Morgan opened a CAPA instead of assigning blame. If she asks people to work crazy hours, “by definition, things will fall through. That’s on me.”
Guarding the Calendar
Morgan blocks 10 hours a week of protected thinking time, in blocks of at least two hours, and assumes two of those hours will get eaten by urgent fires. Once a month she spends a full day offsite reviewing her goals. She also uses AI agents as a kind of chief of staff: they suggest how to use her time blocks, and each week they review what she should have delegated. She’s clear about the limits, though. Asking AI for a regulatory strategy is “a terrible idea,” because it’s good at analyzing the past, and “a lot of what we do is future not having yet been done.” Saying no is harder. Her approach is to decline politely, put the next step on the other person (“please reach back out in Q4”), and ask herself what the output of the call would have been and whether she can send that in an email instead.
Why This Matters
Morgan’s career shows that “pick one” isn’t the only way to build a medtech career. Doing several things only works when each piece has its own strong leaders, discipline about where her own time goes, and a habit of killing ideas early. Her filter applies to any early-stage team: the clinical problem has to work for the masses, and the economics have to hold up. A good idea that doesn’t pass both is still a liability. Her leadership habits, like trusting first, looking at process before blaming people, and being open about her own mistakes, are what let one founder operate at the scale of a whole ecosystem.
What to Watch
Agitated Solutions is in the home stretch of a Phase III trial for its drug-led combination product, and the data and claims coming out of it will be worth watching in non-invasive cardiology, a space mostly made up of pharma and capital equipment. More broadly, Morgan’s use of AI as a sounding board and productivity coach rather than a strategist is a model other lean medtech teams may adopt. And as she and Duane both noted, more women are pitching, but capital still lags. Investors like Engage are trying to change that.
Catch the episode here: https://www.projectmedtech.com/projectmedtechpodcast/episode/2ef40c8e/episode-285-morgan-evans-co-founder-at-agitated-solutions-product-business-model-innovation-in-medtech
Helpful Links



Comments